This compound is primarily used in research focused on targeted protein degradation, particularly in the context of estrogen receptor alpha (ERα). It is designed to selectively degrade ERα, making it a valuable tool in studying breast cancer and other hormone-dependent cancers. By leveraging the PROTAC (Proteolysis Targeting Chimera) technology, it facilitates the removal of ERα from cells, offering insights into therapeutic strategies that aim to inhibit cancer progression. Additionally, it aids in understanding the mechanisms of protein degradation pathways and their potential applications in drug development.